CardioExchange Archive

November 22nd, 2010

Send Us Your Vexing Cases

Anju Nohria, MD

No matter how evidence-based we strive to be in our decision making, we all know that the patient in front of us is never exactly like those enrolled in large clinical trials. Thus at CardioExchange, we have highlighted cases where the application of evidence-based medicine and treatment guidelines is not straight-forward. And often, to our […]

---

November 22nd, 2010

A Clinical Conversation with Harlan Krumholz: CardioExchange and AHA

CardioExchange Editors, Staff

In a Journal Watch Clinical Conversations podcast, Editor Harlan Krumholz discusses CardioExchange and what he thinks of the top research presented at AHA 2010. Hear what Harlan has to say about anacetrapib, rivaroxaban, Tele-HF, and more. Also, see Harlan’s posts at Forbes on remote patient monitoring (including his own Tele-HF study) and on the DEFINE […]

---

November 22nd, 2010

Treating Resistant Hypertension: Singe – Don’t Stent – The Renal Artery

Richard A. Lange, MD, MBA

For years, interventional cardiologists (and radiologists) have been stenting renal arterial stenoses in patients with resistant hypertension, despite evidence that doing so does not lower blood pressure.  It appears we had the right organ (the kidney), but we’ve been doing the wrong procedure. We should have been delivering a singe, not a stent. Advances in endovascular catheter […]

---

November 19th, 2010

Darvon and Darvocet Withdrawn from U.S. Market

Larry Husten, PHD

The FDA announced today that Xanodyne Pharmaceuticals had agreed to withdraw Darvon and Darvocet from the U.S. market. The drugs contain the opioid propoxyphene, which the FDA said “puts patients at risk of potentially serious or even fatal heart rhythm abnormalities.” The FDA said it had asked generic manufacturers of propoxyphene to withdraw their products […]

---

November 18th, 2010

APPRAISE-2 Apixaban in ACS Study Discontinued Due to Increased Bleeding

Larry Husten, PHD

Bristol-Myers Squibb announced on Thursday evening the discontinuation of APPRAISE-2, the phase 3 trial comparing apixaban to placebo in patients with acute coronary syndrome. The decision was based on a recommendation from the data monitoring committee based on “a clinically important increase in bleeding among patients randomized to apixaban,” according to the company press release. […]

---

November 17th, 2010

Negative Trials, Positive Impact

John Ryan, MD

Several Cardiology Fellows who are attending this week’s AHA meeting are blogging together on CardioExchange. The Fellows include Susan Cheng, Madhavi Reddy, John Ryan, and Amit Shah. Check back often to learn about the biggest buzz in Chicago this week — whether it’s a poster, a presentation, or the word in the hallways. You can read […]

---

November 17th, 2010

Early Career Day: Review from the Epi Breakout Session

Amit Shah, MD, MSCR

Several Cardiology Fellows who are attending this week’s AHA meeting are blogging together on CardioExchange. The Fellows include Susan Cheng, Madhavi Reddy, John Ryan, and Amit Shah. Check back often to learn about the biggest buzz in Chicago this week — whether it’s a poster, a presentation, or the word in the hallways. You can read […]

---

November 17th, 2010

Anacetrapib: “Knock-Your-Socks-Off Effect on HDL and a Jaw-Dropping Effect on LDL”

Larry Husten, PHD

Following the failure of torcetrapib in 2006, the future of cholesteryl ester transfer protein (CETP) inhibitors appeared quite troubled. Now, with the results of  DEFINE (Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib), presented at the AHA in Chicago and published online in the New England Journal of Medicine, the future for this novel […]

---

November 16th, 2010

Is There a Statistician in the Room?

Susan Cheng, MD

Several Cardiology Fellows who are attending this week’s AHA meeting are blogging together on CardioExchange. The Fellows include Susan Cheng, Madhavi Reddy, John Ryan, and Amit Shah. Check back often to learn about the biggest buzz in Chicago this week — whether it’s a poster, a presentation, or the word in the hallways. You can read […]

---

November 16th, 2010

Putting the EMPHASIS on Eplerenone for HF

Paul Armstrong, MD

In the EMPHASIS-HF study, aldosterone inhibition with eplerenone reduced the rate of death from cardiovascular causes or heart-failure (HF) hospitalizations by about 37% (compared with placebo) in patients with functional NHYA class II HF. CardioExchange welcomes Paul Armstrong, Professor of Medicine in the Division of Cardiology at the University of Alberta, to answer our questions […]

---